This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sucampo To Present Results From Four Phase 3 Studies Of AMITIZA(R) (lubiprostone) For Opioid-Induced Constipation At PAINWeek 2013

BETHESDA, Md., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") will be presenting data from four separate phase 3 studies evaluating the overall efficacy of AMITIZA (lubiprostone) as a treatment for adults with chronic, non-cancer pain suffering from opioid-induced constipation (OIC). One of the presentations will also include results of AMITIZA's long-term safety and another will highlight novel data indicating that the treatment does not interfere with the analgesic effect of opioids in adult patients. Sucampo will present these data during PAINWeek 2013 in Las Vegas on Thursday, September 5, at 6:15 p.m. PDT.

"Oral lubiprostone has been demonstrated to significantly improve OIC symptoms, and continues to be well tolerated by patients," said Sucampo's Chairman, Chief Executive Officer, and Chief Scientific Officer Ryuji Ueno, M.D., Ph.D., Ph.D. "We are pleased to present these data that build on the body of clinical evidence and real-world experience that support AMITIZA as a treatment for OIC."

AMITIZA is the world's first chloride channel activator that increases intestinal fluid secretion, softens stools and increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic constipation. Based on the data to be presented, AMITIZA does not interfere with the analgesic effect of opioids in adult patients.

The following posters will be presented during the Poster Session at PAINWeek 2013 on Thursday, September 5, between 6:15 p.m. – 7:30 p.m. PDT at Level 2, Condesa 4:

  • A phase 3, randomized, double-blind, placebo-controlled clinical trial of lubiprostone for the treatment of opioid-induced constipation in patients with chronic, non-cancer pain
  • Byron Cryer, MD, Seymour Katz, MD, Taryn R. Joswick, BS, PMP, Gayle R. Dolecek, PD, MPH, Ryuji Ueno, MD, PhD, PhD, Poster 44
  • Lubiprostone for Treatment of Opioid-Induced Constipation Does Not Interfere With Opioid Analgesic Effects in Patients With Non-Cancer Pain
  • Egilius L. H. Spierings, MD, PhD, Taryn Joswick, BS, PMP, Shadreck Mareya, PhD, Yijun Sun, PhD, Ryuji Ueno, MD, PhD, PhD, Poster 60
  • Lubiprostone significantly improves constipation induced by non-methadone opioids in patients with chronic, non-cancer pain: results from a phase 3, randomized, double-blind, placebo-controlled clinical trial
  • M. Mazen Jamal, MD, MPH, Shadreck M. Mareya, PhD, Taryn R. Joswick, BS, PMP, Ryuji Ueno, MD, PhD, PhD, Poster 61
  • Long-term safety and efficacy of lubiprostone in opioid-induced constipation in patients with chronic, non-cancer pain: results from a phase 3, open-label clinical trial
  • Spierings, Egilius L., Joswick, Taryn, Lindner, Elizabeth, Woldegeorgis, Fasil, Ueno, Ryuji, Poster 43

Additional information about the PAINWeek 2013 conference can be found at http://conference.painweek.org/ .

About AMITIZA

AMITIZA (lubiprostone) capsules are indicated for the treatment of chronic idiopathic constipation (CIC) in adults and OIC in adults with chronic, non-cancer pain (24 mcg twice daily). The effectiveness in patients with OIC taking diphenylheptane opioids (e.g., methadone) has not been established. AMITIZA is also indicated for irritable bowel syndrome with constipation (IBS-C) in women > 18 years old (8 mcg twice daily).

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs